Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.
Blockonomi

ARK Invest’s Cathie Wood Pours $41M into Tesla (TSLA), Exits Roku Position Ahead of Holiday

Cathie Wood's ARK Invest purchased $41.2M in Tesla (TSLA) and $2.3M in Bullish while selling $25.3M in Roku shares. See full trade breakdown here.

The only AI glossary you’ll need this year

The rise of AI has brought an avalanche of new terms and slang. Here is a glossary with definitions of some of the most ...

Enterprises lost Claude Fable 5 for a few weeks. New data shows two-thirds had already built their hedge

A new VentureBeat survey of 145 enterprises finds most have hedged their AI model strategy since the Fable 5 blackout, but ...

Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives?

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.